期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

IRESSA联合化疗药物不同次序对肺癌细胞系GLC-82 COX-2表达的影响 被引量：1

Distinct COX-2 expression of IRESSA combinated chemotherapeutics with different successions on GLC-82
下载PDF
导出
摘要 目的:探讨IRESSA以不同次序联合化疗药(奈达铂、多西他赛和酒石酸长春瑞滨)对肺腺癌细胞系GLC-82 COX-2表达的不同作用。方法:流式细胞仪检测IRESSA不同次序联合化疗药奈达铂、多西他赛和酒石酸长春瑞滨时,GLC-82细胞表面COX-2表达情况,RT-PCR法检测COX-2的mRNA表达水平,Western blot检测COX-2蛋白的表达水平。结果:在化疗药之后使用IRESSA,将使GLC-82细胞有较低的COX-2表达率(酒石酸长春瑞滨为23.57%,奈达铂为12.1%,多西他赛为10.12%,P<0.05)、较低的COX-2 mRNA水平(酒石酸长春瑞滨为0.872±0.245,F=28.925,P=0.000;奈达铂为0.362±0.051,F=7.61,P=0.005;多西他赛为0.387±0.041,F=8.064,P=0.003)及较高的COX-2蛋白表达(酒石酸长春瑞滨为0.432±0.062,F=24.928,P=0.000;奈达铂为0.294±0.031,F=150.928,P=0.000;多西他赛为0.061±0.011,F=373.647,P=0.000)。结论:IRESSA和化疗药联合存在最佳方案,后用IRESSA效果优于先用IRESSA。 OBJECTIVE：To investigate the COX 2 contributions of gefitinib eombinated with chemotherapy drug （nedaplatin, docetaxel, vinorelbine） by diverse sequence on lung ear cinoma cell line GLC-82. METHODS：The GLC-82 cell COX-2 expression of nedaplatin, doeetaxel, and vinoreIbine combined with gefitinib of different sequences was measured by flow cytometry, COX-2 mRNA of the different combinations was detected by RT-PCR and COX-2 protein was analysed by Western blot. RESULTS： Applying gefitinib earlier or simultaneous created higher COX-2 expression （vinorelbine： 23.57 %; nedaplatin 12. 1%; docetaxel： 10. 12%. P〈0.05）, mRNA level （vinorelbine： 0.872±0.245,F 28. 925 , P = 0. 000; nedaplatin 0.362±0.051, F= 7.61, P = 0.005; docetaxel： 0.387 ±0.041, F=8. 064, P= 0. 003 ） and more COX-2 protein （vinorelbine： 0. 432±0. 062, F= 24. 928, P = 0. 000; nedaplatin 0.294±0.031, F =150. 928, P =0. 000 ; docetaxel： 0.061±0.011,F 373.647,P=0.000）. CONCLUSION： It is necessary to explore optimal schedule when gefitinib combined with chemotherapy drugs, to use gefitinib after chemotherapy drugs creats better curative effect than that before chemotherapy drugs.
作者 刘全 王建军 潘永成 李劲松 江科
机构地区 华中科技大学附属协和医院胸外科
出处 《中华肿瘤防治杂志》 CAS 2007年第5期345-348,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 肺肿瘤 抗肿瘤联合化疗方案 紫杉烷类 lung neoplasms antineoplastic combined chemotherapy protocols taxoids
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Chang G C,Hsu S L,Tsai J R,et al.Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells[J].Biochemical Pharmacology,2004,68(7):1453-1464.
  • 2Solomon B,Hagekyriakou J,Trivett M K,et al.EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell cacinoma,epidermal growth factor receptor[J].Int J Radiat Oncol Biol Phys,2003,55,(3):713-723.
  • 3Xu J M,Azzariti A,Severino M,et al.The effect of gefitinib incombination with oxaliplatin is schedul dependent in colon cancer lines[J].Cancer Chemother Pharmacol,2003,52(6):442-448.
  • 4Giaccone G,Herbst R S,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer:a phase Ⅲ trial-INTACT1[J].J Clin Oncol,2004,22(5):777-784.
  • 5Soslow R A,Dannenberg A J,Rush D,et al.COX-2 is expressed in human pulmonary,colonic,and mammary tumors[J].Cancer,2000,89(12):2637-2645.
  • 6Howe L R,Dannenberg A J.A role for cyclooxygenase2 inhibitors in the prevention and treatment of cancer[J].Semin Oncol,2002,29(3):111-116.
  • 7Tortora G,Caputo R,Damiano V,et al.Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect[J].Clin Cancer Res,2003,9(4):1566-1572.
  • 8Coffey R J,Hawkey C J,Damstrup L,et al.Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2 basolateral release of prostaglandins and mitogenesis in polarizing colon cancer cells[J].Proc Natl Acad Sci U S A,1997,94(2):657-662.
  • 9Ballif B A,Mincek N V,Barratt J T,et al.Interaction of cyclooxygenases with an apoptosis-and autoimmunity-associated protein[J].Proc Natl Acad Sci U S A,1996,93(11):5544-5549.
  • 10Kinoshita T,Takahashi Y,Sakashita T,et al.Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells[J].Biochim Biophys Acta,1999,1438(1):120-130.

同被引文献19

  • 1Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Dis ease Study 2010[J]. Lancet,2013,380(9859) :2095-2128.
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin,2011,61 (2) :69 -90.
  • 3Morelli M, Cascone T, Troiani T, et al. Sequence dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors[J]. Annals Oncol, 2005, 16 (suppl 4) : iv61-iv68.
  • 4Herbst RS, Prager D, Hermann R, etal. TRIBUTE: a phase Ⅲ trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non- small-cell lung cancer[J]. J Clin Oncol, 2005,23 (25) : 5892- 5899.
  • 5Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in com- bination with gemcitabine and cisplatin in advanced non-small- cell lung cancer: a phase III trial-INTACT 1 [J]. J Clin Oncol, 2004,22 (5) : 777-784.
  • 6Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial [J]. J Clin Oncol, 2007, 25 (12) 1545-1552.
  • 7Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predic-tive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combina- tion with erlotinib[J]. J Clin Oncol, 2005,23 (25) : 5900-5909.
  • 8Lee J, Ignaeio J, Yu C, et at. FAST-ACT: A phase 11 ran- domized double-blind trial of sequential erlotinib and chemo- therapy as firstqine treatment in patients (pts) with stage Ill B/IV non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2008,26(15) :8031-8040.
  • 9Higgins J, Green S. Cochrane Handbook for Systematic Re- views of Interventions Version 5. 0. 2. 2009. The Cochrane Collaboration. 2010.
  • 10Michael M, Pavlakis N, Clingan P, et al. A multi-centre ran- domized, open-label phase 1] trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer[J]. Oncol Rep, 2012,28 (3) : 763-767.

引证文献1

二级引证文献1

中华肿瘤防治杂志
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部